Urogen Pharma (URGN) Stock Price, News & Analysis

Company Overview

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company’s platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure.

UroGen’s lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults. The company is also developing UGN-102, an investigational formulation of mitomycin intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.

Founded in 2004, UroGen is headquartered in Princeton, New Jersey, and has operations connected to Israel, where the company was established. Its commercial activities are primarily focused on the United States, while its clinical development programs are intended to support broader treatment options for patients with urological cancers. Elizabeth Barrett serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $37.20 to $39.04
• 50-Day Range: $36.83 to $50.29
• 52-Week Range: $16.36 to $50.81
• Volume: 349,807 shs
• Average Volume: 820,847 shs
• Market Capitalization: $1.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $52.38
• Consensus Rating: Moderate Buy

Urogen Pharma Stock Analysis - MarketRank™

Urogen Pharma scored higher than 63% of companies evaluated by MarketBeat, and ranked 315th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Urogen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Urogen Pharma has a consensus price target of $52.38, representing about 36.9% upside from its current price of $38.26.

Amount of Analyst Coverage

Urogen Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Urogen Pharma are expected to grow in the coming year, from ($0.20) to $3.49 per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.69% of the float of Urogen Pharma has been sold short.

Short Interest Ratio / Days to Cover

Urogen Pharma has a short interest ratio ("days to cover") of 9.91.

Change versus previous month

Short interest in Urogen Pharma has recently increased by 24.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Urogen Pharma does not currently pay a dividend.

Dividend Growth

Urogen Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.40

News Sentiment

Urogen Pharma has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Urogen Pharma this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for URGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

8 people have added Urogen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Urogen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,037,646.00 in company stock.

Percentage Held by Insiders

4.80% of the stock of Urogen Pharma is held by insiders.

Percentage Held by Institutions

91.29% of the stock of Urogen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:URGN
• CIK: 1668243
• Web: www.urogen.com
• Phone: (646) 768-9780
• Fax: N/A
• Employees: 291
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Urogen Pharma: $52.38
• High Price Target: $75.00
• Low Price Target: $33.00
• Potential Upside/Downside: +34.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$153.49 million
• Net Margins: -51.73%
• Pretax Margin: -51.98%
• Return on Equity: N/A
• Return on Assets: -43.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.80
• Quick Ratio: 3.41

Sales & Book Value

• Annual Sales: $109.79 million
• Price / Sales: 17.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.25) per share
• Price / Book: -17.29

Miscellaneous

• Outstanding Shares: 48,880,000
• Free Float: 46,535,000
• Market Cap: $1.90 billion
• Optionable: Optionable
• Beta: 1.57